- Home
- IRIX vs CLRB Comparison
IRIX vs CLRB Comparison
Compare IRIX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- CLRB
- Stock Information
- Founded
- IRIX 1989
- CLRB 2002
- Country
- IRIX United States
- CLRB United States
- Employees
- IRIX N/A
- CLRB N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- IRIX Health Care
- CLRB Health Care
- Exchange
- IRIX Nasdaq
- CLRB Nasdaq
- Market Cap
- IRIX 16.5M
- CLRB 14.2M
- IPO Year
- IRIX 1996
- CLRB N/A
- Fundamental
- Price
- IRIX $1.12
- CLRB $4.42
- Analyst Decision
- IRIX
- CLRB Hold
- Analyst Count
- IRIX 0
- CLRB 2
- Target Price
- IRIX N/A
- CLRB N/A
- AVG Volume (30 Days)
- IRIX 172.5K
- CLRB 129.9K
- Earning Date
- IRIX 08-12-2025
- CLRB 08-14-2025
- Dividend Yield
- IRIX N/A
- CLRB N/A
- EPS Growth
- IRIX N/A
- CLRB N/A
- EPS
- IRIX N/A
- CLRB N/A
- Revenue
- IRIX $49,744,000.00
- CLRB N/A
- Revenue This Year
- IRIX $9.61
- CLRB N/A
- Revenue Next Year
- IRIX N/A
- CLRB N/A
- P/E Ratio
- IRIX N/A
- CLRB N/A
- Revenue Growth
- IRIX 0.09
- CLRB N/A
- 52 Week Low
- IRIX $0.78
- CLRB $4.33
- 52 Week High
- IRIX $2.14
- CLRB $68.70
- Technical
- Relative Strength Index (RSI)
- IRIX 42.12
- CLRB 36.43
- Support Level
- IRIX $1.27
- CLRB $4.39
- Resistance Level
- IRIX $1.34
- CLRB $5.09
- Average True Range (ATR)
- IRIX 0.08
- CLRB 0.35
- MACD
- IRIX -0.03
- CLRB 0.07
- Stochastic Oscillator
- IRIX 10.85
- CLRB 8.50
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.